Some individuals remain at high risk for developing cardiovascular disease even after preventative treatment with cholesterol-lowering medications. This persistent risk has been linked to triglyceride levels, which can remain ...
Jul 11, 2016
0
2
Women with type 2 diabetes and high cholesterol are less likely than their male peers to reach treatment goals to lower their "bad" cholesterol, or low-density lipoprotein (LDL) cholesterol, despite access to cholesterol-lowering ...
Jun 23, 2014
0
0
Evolocumab (trade name: Repatha) has been approved since July 2015 for two therapeutic indications: on the one hand, for hypercholesterolaemia or mixed dyslipidaemia, and on the other, for homozygous familial hypercholesterolaemia. ...
Dec 22, 2015
0
0
A common mutation in the TM6SF2 gene raises liver values but at the same time improves blood lipid values in healthy children, according to a recent study from the University of Eastern Finland. Children who carry the gene ...
Jan 13, 2016
0
4
The enzyme that 'loads up' fat-carrying particles in the liver before they are transported around the body has been identified for the first time by scientists at the University of Warwick.
Jan 28, 2019
0
0
Very aggressive reduction of LDL-cholesterol to ultra-low levels was associated with progressively fewer cardiovascular events and appears to pose no safety concerns in patients with stable atherosclerotic cardiovascular ...
Aug 28, 2017
0
0
Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or "bad" cholesterol, also significantly lowers the risk of cardiovascular events ...
Mar 17, 2017
0
0
If you're one of the one in three Australians whose New Year's resolution involved losing weight, it's likely you're now contemplating what weight-loss goal you should actually be working towards.
Feb 5, 2024
0
0
A new study published in Circulation: Cardiovascular Quality and Outcomes from the Family Heart Foundation—a patient-centered research and advocacy nonprofit organization dedicated to improving the lives of families impacted ...
Feb 20, 2024
0
2
(HealthDay)—In patients with type 2 diabetes being treated with a dipeptidyl peptidase-4 inhibitor (DPP4-I), use of anagliptin (ANA) may improve low-density lipoprotein cholesterol (LDL-C) levels, with the effect mediated, ...
Sep 19, 2017
0
1
